Interactions between a novel cholinergic ion channel agonist, SIB-1765F and L-DOPA in the reserpine model of Parkinson's disease in rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 280, Issue 1, 1997, Pages 393-401

  Menzaghi, Frédérique ^a   Whelan, Kevin T ^a   Risbrough, Victoria B ^a   Rao, Tadimeti S ^a   Lloyd, G Kenneth ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 ETHYNYL 5 (1 METHYL 2 PYRROLIDINYL)PYRIDINE FUMARATE; AMANTADINE; BENSERAZIDE; CHOLINERGIC RECEPTOR STIMULATING AGENT; DEXAMPHETAMINE; LEVODOPA; METIROSINE; NICOTINE; RESERPINE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; CHOLINERGIC SYSTEM; CONTROLLED STUDY; DEGENERATIVE DISEASE; DOPAMINE RELEASE; DRUG EFFICACY; DRUG POTENTIATION; EXPERIMENTAL MODEL; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LOCOMOTION; MALE; MOTOR ACTIVITY; NEUROTRANSMITTER RELEASE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

AMANTADINE; ANIMALS; ANTIPARKINSON AGENTS; CORPUS STRIATUM; DEXTROAMPHETAMINE; DOPAMINE; ION CHANNELS; LEVODOPA; MALE; MOTOR ACTIVITY; NICOTINIC AGONISTS; OLFACTORY PATHWAYS; PARKINSON DISEASE; PYRIDINES; PYRROLIDINES; RATS; RATS, SPRAGUE-DAWLEY; RESERPINE;

EID: 0030933637     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. AGID, Y., RUBERG, M., DUBOIS, B. AND JAVOY-AGID, F.: Biochemical substrates of mental disturbances in Parkinson's disease. Adv. Neurol. 40: 211-8, 1984.
2. AKAIKE, A., TAMURA, Y., YOKOTA, T., SHIMOHAMA, S. AND KIMURA, J.: Nicotine-induced protection of cultured cortical neurons against N-methyl-D-aspartate receptor-mediated glutamate cytotoxicity. Brain Res. 644: 181-187, 1994.
3. ARQUEROS, L., NAQUIRA, D. AND ZUNINO, E.: Nicotine-induced release of catecholamines from rat hippocampus and striatum. Biochem. Pharmacol. 27: 2667-2674, 1978.
4. AUBERT, I., ARAUJO, D. M., CECYRE, D., ROBITAILLE, Y., GAUTHIER, S. AND QUIRION, R.: Comparative alterations of nicotinic and muscarinic binding sites in Alzheimer's and Parkinson's diseases. J. Neurochem. 58: 529-541, 1992.
5. BALFOUR, D. J. K., BENWELL, M. E. M. AND VALE, A. L.: Studies on the role of mesolimbic dopamine in behavioural responses to chronic nicotine. In Effect of Nicotine on Biological Systems, ed. by F. Adlkofer and K. Thurau, pp. 407-416. Birkauser, Berlin. 1991.
6. BARON, J. A.: Cigarette smoking and Parkinson's disease. Neurology 36: 1490- 1496, 1986.
7. BENOWITZ, N. L.: Clinical pharmacology of nicotine. Ann. Rev. Med. 37: 21-32, 1986.
8. BLAHA, C. D. AND WINN, P.: Modulation of dopamine efflux in the striatum following cholinergic stimulation of the substantia nigra in intact and pedunculopontine tegmental nucleus-lesioned rats. J. Neurosci. 13: 1035-1044, 1993.
9. BOUCHENAFA, O., SHUHAIBER, J. AND LITTLETON, J. M.: Nicotine has neuroprotecive effects against excitatory amino-acid-induced neurotoxicity in neocortical cultures. Behavioral Pharmacol. 6: 616, 1995.
10. CARLSSON, A.: Monoamine-depleting drugs. Pharmac. Ther. 1: 393-400, 1975a.
11. CARLSSON, A.: Drugs acting through dopamine release. Pharmac. Ther. 1: 401-405, 1975b.
12. CLARKE, P. B. S. AND PERT, A.: Autoradiographic evidence for nicotinic receptors on nigrostriatal and mesolimbic dopaminergic neurons. Brain Res. 348: 355-358, 1985.
13. CLARKE, P. B. S., F. U., D. S., KAKUBOVIC, A. AND FIBIGER, H. C.: Evidence that mesolimbic dopaminergic activation underlies the locomotor stimulant action of nicotine in rats. J. Pharm. Exp. Ther. 246: 701-708, 1988.
14. COLPAERT, F. C.: Pharmacological characteristics of tremor, rigidity and hypokinesia induced by reserpine in rat. Neuropharmacology 26: 1431-40, 1987.
15. COLEMAN, R. J.: Current drug therapy for Parkinson's disease. A review. Drugs Aging 2: 112-124, 1992.
16. COOPER, J. A., SAGAR, H. J., DOHERTY, S. M., JORDAN, N., TIDSWELL, P. AND SULLIVAN, E. V.: Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease. A follow-up study of untreated patients. Brain 115: 1701-1725, 1992.
17. COOPER, J. A., SAGAR, H. J., TIDSWELL, P. AND JORDAN, N.: Slowed central processing in simple and go/no-go reaction time tasks in Parkinson's disease. Brain 117:517-529, 1994.
18. COSFORD, N. D. P., BLEICHER, L., HERBAUT, A., MCC. A. L.L. U. M. S., VERNIER, J-M., DAWSON, H., WHITTEN, J. P., ADAMS, P., CHAVEZ-NORIEGA, L., CORREA, L. D., CRONA, J. H., MAHAFFY, L. S., MENZAGHI, F., RAO, T. S., REID, R. T., SACAAN, A. I., SANTORI, E. M., STAUDERMAN, K. A., WHELAN, K. D., LLOYD, G. K. AND MCDONALD, I. A.: (S)-(-)-5-Ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine maleate (S. I. B.-1508Y): A novel antiparkinsonian agent with selectivity for neuronal nicotinic acetylcholine receptors. J. Med. Chem. 39: 3235-3237, 1996.
19. DAMHMA, G., DAY, J. AND FIBIGER, H. C.: Lack of tolerance to nicotine-induced dopamine release in the nucleus accumbens. Eur. J. Pharmacol. 168: 363-368, 1990.
20. DANYSZ, W., GOSSEL, M., ZAJACZKOWSKI, W., DILL, D. AND QUACK, G.: Are NMDA antagonistic properties relevant for antiparkinsonian-like activity in rats? Case of amantadine and memantine. J. Neural Transm. 7: 155-166, 1994.
21. DECINA, P., CARACCI, G., SANDIK, R., BERMAN, W., MUKHERJEE, S. AND SCAPICCHIO, P.: Cigarette smoking and neuroleptic-induced parkinsonism. Biol. Psychiat. 28: 502-508, 1990.
22. FAGERSTROM, K. O., POMERLEAU, O., GIORDANI, B. AND STELSON, F.: Nicotine may relieve symptoms of Parkinson's disease. Psychopharmacology 116: 117-119, 1994.
23. FIBIGER, H. C.: The neurobiological substrates of depression in Parkinson's disease: A hypothesis. Can. J. Neurol. Sci. 11: 105-107, 1984.
24. GERLACH, M., JELLINGER, K. AND RIEDERER, P.: The possible role of noradrenergic deficits in selected signs of Parkinson's disease. In Noradrenergic Mechanisms in Parkinson's Disease, ed. by M. Briley and M. Marien M, pp. 59-71, CRC Press, Boca Raton, FL, 1994.
25. GIORGUIEFF-CHESSELET, M. F., KEMEL, M. L., WANDSCHEER, D. AND GLOWINSKI, J.: Regulation of dopamine release by presynaptic nicotinic receptors in rat striatal slices: Effect, of nicotine in a low concentration. Life Sci, 25: 1257-1262, 1979.
26. H. U., L., DONNELLY-ROBERTS, D., ARNERIC, S. P., SULLIVAN, J. P.: In vitro cytoprotective properties of the novel cholinergic channel activator (CHCA), ABT418. Soc. Neuroci. Abs. 21: 607, 1995.
27. ISHIKAWA, A. AND MIYATAKE, T.: Effects of smoking in patients with early-onset Parkinson's disease. J. Neurol. Sci. 117; 28-32, 1993.
28. JACKISCH, R., LINK, T., NEUFANG, B. AND KOCH, R.: Studies on the mechanism of action of the antiparkinsonian drugs memantine and amantadine-no evidence for direct dopaminomimetic or antimuscarinic properties. Arch. Int. Pharmacodyn. Ther. 320: 21-42, 1992.
29. JANSON, A. M., FUXE, K. AND GOLDSTEIN, M.: Differential effects of acute and chronic nicotine treatment on MPTP-(1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine) induced degeneration of nigrostriatal dopamine neurons in the black mouse. Clin. Invest. 70: 232-238, 1992.
30. JANSON, A. M. AND MOLLER, A.: Chronic nicotine treatment counteracts nigral cell loss induced by a partial mesodiencephalic hemitransection: an analysis of the total number and mean volume of neurons and glia in substantia nigra of the male rat. Neuroscience 57: 931-941, 1993.
31. JONES, G. M., M., SAHAKIAN, B. J., LEVY, R., WARBURTON, D. M. AND GRAY, J. A.: Effects of subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer's disease. Psychopharmacology 108: 485-494, 1992.
32. KLOCKGETHER, T. AND TURSKI, L.: NMDA antagonists potentiate antiparkinsonian actions of L-DOPA in monoamine-depleted rats. Ann. Neurol. 28: 539-546, 1990.
33. KORNHUBER, J., WELLER, M., SCHOPPMEYER, K. AND RIEDERER, P.: Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J. Neural Transm. 43: 91-104, 1994.
34. LANGE, K. W., WELLS, F. R., JENNER, P. AND MARSDEN, C. D.: Altered muscarinic and nicotinic receptor densities in cortical and subcortical brain regions in Parkinson's disease. J. Neurochem. 60: 197-203, 1993.
35. LEIKOLA-PELHO, T. AND JACKSON, D. M.: Preferential stimulation of locomotor activity by ventral tegmental microinjections of (-)-nicotine. Pharmacol. Toxicol. 70: 50-52, 1992.
36. LEVIN, B. E., LLABRE, M. M. AND WEINER, W. J.: Cognitive impairments associated with early Parkinson's disease. Neurology 39: 557-561, 1989.
37. LLOYD, G. K., DAVIDSON, L. AND HORNYKIEWICZ, O.: The neurochemistry of Parkinson's disease: Effect of L-DOPA therapy. J. Pharmacol. Exp. Ther. 195: 453-64, 1975.
38. LLOYD, G. K., RAO, T. S., SACAAN, A., REID, R., CORREA, L. D., WHELAN, K., RISBROUGH, V. AND MENZAGHI, F.: SIB-1765F, a novel nicotinic agonist: Profile in models of extrapyramidal motor dysfunction. Soc. Neurosci. Abs, 21: 11.10, 1995.
39. LLOYD, G. K.: Subtype selective nicotinic receptor agonists for the treatment of the motor and non-motor dysfunctions of Parkinson's disease. Movement Disorders 11(Suppl. 1): 25, 1996.
40. MARIN, P., MAUS, M., DESAGHER, S., GLOWINSKI, J. AND PREMONT, J.: Nicotine protects cultured striatal neurons against N-methyl-D-aspartate receptor-mediated neurotoxicity. Neuroreport 5: 1977-1980, 1994.
41. MARSHALL, J. AND SCHNIEDEN, H.: Effect of adrenaline, noradrenaline, atropine and nicotine on some types of human tremor, J. Neurol. Neurosurg. Psychiatry 29: 214-218, 1966.
42. MAYBERG, H. S. AND SOLOMON, D. H.: Depression in Parkinson's disease: A biochemical and organic viewpoint. In Behavioral Neurology of Movement Disorders, vol. 65, ed. by W. J. Weiner and A. E. Lang, pp. 49-60, Advances in Neurology, Raven Press, Ltd., New York, 1995.
43. MENZAGHI, F., WHELAN, K. T., REID, R., SACAAN, A. I., RISBROUGH, V. B., RAO, T. S. AND LLOYD, G. K.: SIB-1765F: A novel nicotinic agonist with locomotor stimulant properties in rats. Soc. Neurose. Abs. 21: 247.5, 1995.
44. MOLL, H.: The treatment of post-encephalitic parkinsonism by nicotine. Br. Med. J. 1: 1079-1081, 1926.
45. MORENS, D. M., GRANDINETTI, A., REED, D., WHITE, L. R. AND ROSS, G. W.: Cigarette smoking and protection from Parkinson's disease: False association or etiologic clue? Neurology 45: 1041-1051, 1995.
46. Mum, J. L., EVERITT, B. J. AND ROBBINS, T. W.: Reversal of visual attention dysfunction following lesions of the cholinergic basal forebrain by physostigmine and nicotine but not by the 5-HT3 receptor antagonist, ondansetron, Psychopharmacology 188: 82-92, 1995.
47. MUSEO, E. AND WISE, R. A.: Microinjections of a nicotinic agonist into dopamine terminal fields: Effects on locomotion. Pharmacol. Biochem. Behav. 37: 113-116, 1990.
48. NEWHOUSE, P. A., SUNDERLAND, T., TARIOT, P. N., BLUMHARDT, C. L., WEINGARTNER, H., MELLOW, A. AND MURPHY, D. L.: Intravenous nicotine in Alzheimer's disease: A pilot study. Psychopharmacology 95: 171-175, 1988.
49. NEWHOUSE, P. A., POTTER, A., CORWIN, J. AND LENOX, R.: Modeling the nicotinie receptor loss in dementia using the nicotinic antagonist mecamylamine-effects on human cognitive functioning. Drug Dev. Res. 31: 71-79, 1994.
50. OWEN, A. M., JAMES, M., LEIGH, P. N., SUMMERS, B. A., MARSDEN, C. D., QUINN, N. P., SAHAKIAN, B. J. AND ROBBINS, T. W.: Frontostriatal cognitive deficits different stages of Parkinson's disease. Brain 115: 1727-1751, 1992.
51. PRASAD, C., IKEOAMI, H., SHIMIZU, I. AND ONAIVI, E. S.: Chronic nicotine intake decelerates aging of nigrostriatal dopaminergic neurons, Life Sci. 54:1169-1184, 1994.
52. PRITCHARD, W. S., ROBINSON, J. H. AND GUY, T. D.: Enhancement of continuous performance task reaction time by smoking in non-deprived smokers, Psychopharmacology 108: 437-442, 1992.
53. RAO, T. S., SACAAN, A. I., REID, R., CORREA, L., ADAMS, P., BLEICHER, L., COSFORD, N., MCDONALD, I. AND LLOYD, G. K.: In vitro characterization of SIB-1765F, a novel nicotinic agonist. Soc. Neurosci. Abs. 21: 247.4, 1995.
54. RAO, T. S., CORREA, L. D., REID, R. AND LLOYD, G. K.: Evaluation of antinociceptive effect of neuronal nicotinic acetylcholine receptor (NAChR) Ligands in the rat tail-flick assay. Neuropharmacology 35: 393-405, 1996.
55. REAVILL, C. AND STOLERMAN, I. P.: Locomotor activity in rats after administration of nicotinic agonists intracerebrally. Br. J. Pharmacol. 99: 273-278, 1990.
56. RICHARDSON, S. A. AND TIZABI, Y.: Hyperactivity in the offspring of nicotine-treated rats: Role of the mesolimbic and nigrostriatal dopaminergic pathways. Pharmacol. Biochem. Behav. 47: 331-337, 1994.
57. RINNE, J. O., MYLLYKYLA, T., LONNBERG, P. AND MARJAMAKI, P.: A postmortem study of brain nicotinic receptors in Parkinson's and Alzheimer's Brain Res. 547: 167-170, 1991.
58. RUBERG, M., PLOSKA, A., JAVOY-AGID, F. AND AGID, Y.: Muscarinic binding choline acetyltransferase activity in parkinsonian subjects with reference to dementia. Brain Res. 232: 129-139, 1982.
59. RUSTED, J. M. AND WARBURTON, D. M.: Facilitation of memory by post-trial administration of nicotine: Evidence for an attentional explanation. Psycho-pharmacology 108:452-455, 1992.
60. SACAAN, A. I., DUNLOP, J. L. AND LLOYD, G. K.: Pharmacological characterization of neuronal acetylcholine gated ion channel receptor-mediated hippocampal norepinephrine and striatal dopamine release from rat brain slices. J. Pharm. Exp. Ther. 274: 224-230, 1995.
61. SERSHEN, H., HASHIM, A., WIENER, H. L. AND LAJTHA, A.: Effect of chronic oral nicotine on dopaminergic function in the MPTP-treated mouse. Neurosci. Lett. 93: 270-274, 1988.
62. SKUZA, G., ROGOZ, Z., QUACK, G. AND DANYSZ, W.: Memantine, amantadine and L-deprenyl potentiate the action of L-DOPA in monoamine-depleted rats. J. Neural Transm. 98: 57-67, 1994.
63. SMITH, P. K., KROHN, R. I., HERMANSON, G. I., MALIA, A. K., GARTNER, F. H., PROVCMAZO, M. D., FUJIMOTO, E. K., GOEKE, N. M., OKON, B. J. AND KLENK, D. C.: Measurement of protein using bicinchonic acid. Anal. Biochem, 150: 76-85, 1985.
64. STOOF, J. C., BOOIJ, J., DRUKARCH, B. AND WOLTERS, E. C.: The anti-parkinsonian drug amantadine inhibits the N-methyl-D-aspartic acid-evoked release of acetylcholine from rat neostriatum in a non-competitive way. Eur. J. Pharmacol. 213: 439-443, 1992.
65. VAGLINI, F., FASCETTI, F., FORNAI, F., MAGGIO, R. AND CORSINI, G. U.: Nicotine prevents experimental parkinsonism in rodents. Soc. Neurosci. Abs. 20: 1465, 1994.
66. WHITEHOUSE, P. J., MAKTINO, A. M., MARCUS, K. A., ZWEIG, R. M., SINGER, H. S., PRICE, D. L. AND KELLAR, K. J.: Reductions in acetylcholine and nicotine binding in several degenerative diseases, Arch. Neurol. 45: 722-724, 1988.